Stock 0JW9 MEI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MEI Pharma, Inc. London S.E.

Equities

0JW9

US55279B3015

Market Closed - London S.E.
Other stock markets
 08:05:44 01/03/2023 pm IST 		5-day change 1st Jan Change
4.336 USD -91.91% Intraday chart for MEI Pharma, Inc. +53.49% -25.50%
09/05 MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
11/04 MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data CI

Evolution of the average Target Price on MEI Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

92b4a4075ad690bd60ff96bf371c9e.XU_lQv7XYepyzTePIyAp-9XWN8Qjr_fRJiLVUY3qWDs.J3qwKKu5NpAw_UbWRnJPy6S0QvRW4rqGSH27Ptm7PFZvN4MgrOEL2hiaQA~166b47e0151b803d2fa73744dfd69ccc

Analyst Recommendations on MEI Pharma, Inc.

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40 MT
BTIG Downgrades MEI Pharma to Neutral From Buy MT
Truist Securities Downgrades MEI Pharma to Hold From Buy MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13 MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6 MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4 MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.9 USD
Average target price
22.67 USD
Spread / Average Target
+681.58%
High Price Target
42 USD
Spread / Highest target
+1,348.23%
Low Price Target
6 USD
Spread / Lowest Target
+106.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MEI Pharma, Inc.

Stifel Nicolaus
HC Wainwright
Jefferies & Co.
Truist Securities
BTIG
Wells Fargo Securities
Brookline Capital Markets

Ratings for MEI Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MEIP Stock
  4. 0JW9 Stock
  5. Consensus MEI Pharma, Inc.